Perylene-3,4:9,10-tetracarboxylic dianhydride

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1972

Report date:

1972

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

according to internal standard method

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

Perylene-3,4:9,10-tetracarboxylic dianhydride

EC Number:

204-905-3

EC Name:

Perylene-3,4:9,10-tetracarboxylic dianhydride

Cas Number:

128-69-8

Molecular formula:

C24H8O6

IUPAC Name:

7,18-dioxaheptacyclo[14.6.2.2²,⁵.0³,¹².0⁴,⁹.0¹³,²³.0²⁰,²⁴]hexacosa-1(23),2,4,9,11,13,15,20(24),21,25-decaene-6,8,17,19-tetrone

Details on test material:

- Name of test material (as cited in study report): 3,4,9,10-Perylentetracarbonsäuredianhydrid
- Substance type: pure peroxy acid
- Physical state: solid (pellets)

Test animals

Species:

mouse

Strain:

other: Kisslegg

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: average weight males: 26.0 g, females: 23.3 g

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

CMC (carboxymethyl cellulose)

Remarks:

aequous suspension

Details on exposure:

- Concentration in vehicle: 25%
- applied amount: 32, 25.6, 20, 16, 12.8 and 10 ml/kg

Doses:

2500, 3200, 4000, 5000, 6400 and 8000 mg/kg

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 3 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: mortality observed

Mortality:

All animals treated with 8000, 6400 and 5000 mg/kg died. Both at 4000 mg/kg and 3200 mg/kg 4/5 males and 2/5 females died. At 2500 mg/kg, 3/5 males died.

Clinical signs:

8000 -4000 mg/kg: Dyspnea, atony, apathy
3200 and 2500 mg/kg: Dyspnea
All surviving animals recovered within 14 days.

Gross pathology:

general organ coloration, intra-abdominal substance deposit. In some animals slightly enlarged spleen, intra-abdominal agglutinations and blunt edges of the liver.

Any other information on results incl. tables

In a pretest 5 mice per sex and dose group were treated with dose levels of 6400, 5000, 4000, 3200, 2500, 2000, 1250 and 1000 mg/kg. Dyspnea and atony were observed, deaths occurred from 1250 mg/kg and up. At autopsy general organ coloration and intra-abdominal substance deposits were reported. In addition, in some animals showed blunt liver edges, adhesions between liver and the intestinal bundle and agglutinations between organs.

In a second pretest 5 mice per sex and dose were treated with doses of 3200, 2500, 2000, 1600, 1250, 1000 and 800 mg/kg. Deaths occurred only at the high dose (1/5 females), dyspnea and atony were observed, at autopsy agglutinations, blunt liver edges, general organ coloration and intra-abdominal substance deposits were reported.

Applicant's summary and conclusion

Conclusions:

LD50 ca 3000 mg/kg bw